Chemlex raises USD45 million for AI drug discovery lab in Singapore

AI-for-science startup ChemLex raises USD 45M, launching self-driving lab for drug discovery in Singapore

08 Dec 2025 3 min read

Chemlex raises USD45 million for AI drug discovery lab in Singapore

Photo credit: Chemlex

This press release was issued by ChemLex.

ChemLex, a next-generation AI-for-science company, today announced the establishment of its global headquarters and self-driving laboratory in Singapore, alongside the close of a USD 45 million funding round led by Granite Asia.

Founded in 2022, ChemLex develops AI technologies that radically accelerate chemical discovery for the pharmaceutical industry, significantly reducing time-to-market. In just three and a half years, it has grown to support more than 70 customers worldwide, including six of the world’s top ten pharmaceutical companies. This surge reflects a larger industry shift as analysts expect the AI-powered drug discovery market to jump from USD 3.6B in 2024 to nearly USD 50B by 2034.

At the core of ChemLex’s platform is a 24/7 autonomous chemistry system that accelerates chemical discovery, making it far more cost-eZicient and significantly more sustainable than traditional laboratory methods. Driving this is an innovative AI- powered, fully automated synthesis line, which runs experiments autonomously, captures data in real-time, and transforms chemical discovery from a stop-start process into a smooth workflow.

The new funding will support the hiring of more hardware and software engineers, as well as chemists in Singapore, enabling the company to serve a broader pipeline of pharmaceutical and materials science projects.

Photo credit: Chemlex

“We’re building an R&D engine that compresses months of synthesis and optimisation into weeks or even days, transforming both the speed and certainty of discovery. Singapore strengthens this eZort and provides us an ecosystem to scale rapidly and support partners globally who need this capability now.”

Sean Lin

Founder and CEO

ChemLex

“AI-enabled chemistry is creating one of the most important industrial transitions of the decade, and ChemLex sits in that sweet spot, turning that shift into a business advantage with a platform that can accelerate molecule design and manufacturing at scale. This is the type of deeptech company that can reshape supply chains, shorten development timelines, and unlock new economic value, and Singapore gives them the foundation to grow.”

Yinghui Kuang

Partner

Granite Asia

ChemLex also signed a memorandum of understanding with the Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development. This collaboration seeks to accelerate next-generation small molecule drug discovery through advanced automation.

“We first met ChemLex in 2023, and since then we’ve seen the company grow from a promising startup to a global innovator in AI and automation-driven chemical synthesis. As ChemLex’s first Singapore partner, we are thrilled to expand our collaboration through the MOU. This partnership reinforces our shared vision of accelerating drug discovery and development through cutting-edge technology, ultimately bringing safer, more eZective therapies to patients faster. By combining EDDC’s drug development expertise with ChemLex’s automation and AI capabilities, we aim to shorten timelines, reduce costs, and deliver innovative treatments that improve lives in Singapore and globally.”

Prof. Damian O'Connell

Experimental Drug Development Centre

These initiatives align with the Singapore Economic Development Board’s (EDB) eZorts to build a more resilient, innovation-ready life sciences ecosystem.

Photo credit: Chemlex

“ChemLex’s decision to anchor its global R&D headquarters and AI laboratory in Singapore reflects how companies can leverage the confluence of our strengths in deep tech and biomedical sciences ecosystem, to launch breakthrough innovations. We look forward to supporting more like-minded partners like ChemLex, to accelerate scientific discoveries that will benefit patients worldwide.”

Goh Wan Yee

Senior Vice President and Head

EDB